tirabrutinib
Showing 1 - 8 of 8
Relapsed/Refractory B-cell Malignancies Trial in France, United Kingdom (Tirabrutinib)
Completed
- Relapsed/Refractory B-cell Malignancies
- Tirabrutinib
-
Lille, Nord, France
- +5 more
Mar 23, 2022
Part A: Relapsed or Refractory Primary CNS Lymphoma (PCNSL), Part B: Newly Diagnosed, Treatment naïve PCNSL Trial in United
Recruiting
- Part A: Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Part B: Newly Diagnosed, Treatment naïve PCNSL
- Tirabrutinib
-
Duarte, California
- +29 more
Jun 15, 2022
Chronic Spontaneous Urticaria Trial (Tirabrutinib, Placebo)
Withdrawn
- Chronic Spontaneous Urticaria
- Tirabrutinib
- Placebo
- (no location specified)
Jul 22, 2021
Chronic Lymphocytic Leukemia Trial in Germany (Tirabrutinib, Idelalisib, Obinutuzumab)
Completed
- Chronic Lymphocytic Leukemia
- Tirabrutinib
- +2 more
-
Frankfurt, Brandenburg, Germany
- +13 more
Dec 24, 2021
Chronic Lymphocytic Leukemia Trial in Germany (Tirabrutinib, Entospletinib, Obinutuzumab)
Completed
- Chronic Lymphocytic Leukemia
- Tirabrutinib
- +2 more
-
Aschaffenburg, Germany
- +14 more
Dec 17, 2021
Non Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia Trial in France, United Kingdom (Tirabrutinib)
Completed
- Non Hodgkins Lymphoma
- Chronic Lymphocytic Leukaemia
- Tirabrutinib
-
Lille, France
- +5 more
Feb 22, 2021
Rheumatoid Arthritis Trial in United States (Tirabrutinib, Placebo)
Completed
- Rheumatoid Arthritis
- Tirabrutinib
- Placebo
-
Sacramento, California
- +8 more
Aug 21, 2020